

## GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGENTS

### Applies To:

#### PREFERRED

semaglutide subcutaneous injection (OZEMPIC)

semaglutide tablet (RYBELSUS)

dulaglutide subcutaneous injection (TRULICITY),

liraglutide subcutaneous injection (VICTOZA),

#### NON-PREFERRED

exenatide subcutaneous injection (BYETTA),

exenatide extended-release subcutaneous injection (BYDUREON),

### Diagnosis Considered for Coverage:

- Diabetes Mellitus - Type 2 (DM-2)

### Coverage Criteria:

#### For type 2 diabetes mellitus:

- Diagnosis confirmed by one of the following laboratory test results:

- |  |
|--|
| <ul style="list-style-type: none"> <li>a. A1C of <math>\geq 6.5\%</math>, or</li> <li>b. Fasting blood glucose of <math>\geq 126\text{mg/dl}</math>, or</li> <li>c. Oral glucose tolerance test (OGTT) <math>\geq 200\text{mg/dl}</math>,</li> </ul> |
|--|

AND

- Not being used in combination with another GLP-1 RA agent (e.g. Adlyxin, Bydureon, Byetta, Ozempic, Soliqua, Rybelsus, Trulicity, Victoza, Xultophy, Mounjaro, Wegovy, Saxenda),

AND

- Dose does not exceed FDA label maximum,

AND

- Meets pre-requisite therapy requirement below:

Drug	Pre-requisite Therapy
Rybelsus	<ul style="list-style-type: none"> <li>• One of the following:                             <ul style="list-style-type: none"> <li>○ Inadequate response, intolerable side effect, or contraindication with metformin,</li> <li>OR</li> <li>○ Patient requires combination therapy and has an A1C of 7.5% or greater</li> </ul> </li> </ul>

	<b>Trulicity Ozempic Victoza</b>	<ul style="list-style-type: none"> <li>• One of the following: <ul style="list-style-type: none"> <li>○ Inadequate response, intolerable side effect, or contraindication with metformin, OR</li> <li>○ Patient requires combination therapy and has an A1C of 7.5% or greater, OR</li> <li>○ Patient has atherosclerotic cardiovascular disease indicators of high risk [e.g. established cardiovascular disease or multiple cardiovascular risk factors].</li> </ul> </li> </ul>
	<b>Bydureon Byetta</b>	<ul style="list-style-type: none"> <li>• One of the following: <ul style="list-style-type: none"> <li>○ Inadequate response, intolerable side effect, or contraindication with metformin, OR</li> <li>○ Patient requires combination therapy and has an A1C of 7.5% or greater,</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Inadequate response or intolerable side effect with TWO preferred GLP-1 RAs (e.g. Ozempic, Trulicity, Victoza, Rybelsus)</li> </ul>

**Coverage Duration:** one year

**References:**

1. American Diabetes Association. Standard of Medical Care in Diabetes - 2023. Diabetes Care 2023;46(Supplement\_1):S140–S157. <https://doi.org/10.2337/dc23-S009>
2. Byetta [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2021.
3. Bydureon BCise [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2021.
4. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2021.
5. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2021.
6. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company. 2021.
7. Victoza [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2021.

Effective Date: 5/3/2023